Lipoprotein-associated phospholipase A2 (Lp-PLA2) as a therapeutic target to prevent retinal vasopermeability during diabetes

New Research In

Edited by Jian-xing Ma, University of Oklahoma Health Science Center, Oklahoma City, OK, and accepted by Editorial Board Member Jeremy Nathans May 6, 2016 (received for review July 22, 2015)

201514213

DOI:

PubMed:

Published By:

Print ISSN:

Online ISSN:

History:

Freely available online through the PNAS open access option.

^aCentre for Experimental Medicine, School of Medicine, Dentistry and Biomedical Science, Queen's University Belfast, Royal Victoria Hospital, Belfast, United Kingdom;
^bDepartment of Cell Biology, University College London Institute of Ophthalmology, London EC1V 9EL, United Kingdom;
^cSchool of Science & Engineering, Teesside University, Middlesbrough TS1 3BA, United Kingdom;
^dPlatform Technology Sciences, GlaxoSmithKline, King of Prussia, PA 19406;
^eOphthalmology Discovery Performance Unit, GlaxoSmithKline, King of Prussia, PA 19406;
^fOphthalmology Discovery Performance Unit, GlaxoSmithKline, Stevenage, United Kingdom;
^gOcular Biology and Therapeutics, University College London Institute of Ophthalmology, London EC1V 9EL, United Kingdom

Edited by Jian-xing Ma, University of Oklahoma Health Science Center, Oklahoma City, OK, and accepted by Editorial Board Member Jeremy Nathans May 6, 2016 (received for review July 22, 2015)

↵¹P.T. and A.W.S. contributed equally to this work.
↵²To whom correspondence may be addressed. Email: a.stitt{at}qub.ac.uk or p.turowski{at}ucl.ac.uk.

Author contributions: F.J.L., P.A., P.T., and A.W.S. designed research; P.C., B.-A.K., V.P., J.G., M.H.S., N.H., M.B., D.G., P.J.L., P.T., and A.W.S. performed research; F.J.L. contributed new reagents/analytic tools; P.C., B.-A.K., J.G., D.G., and P.T. analyzed data; and P.C., P.A., P.T., and A.W.S. wrote the paper.
Conflict of interest statement: The authors M.B., F.J.L., D.G., and P.A. are (or have been) employed by GlaxoSmithKline. The funding of this research has been through a grant provided by GlaxoSmithKline.
This article is a PNAS Direct Submission. J.-x.M. is a guest editor invited by the Editorial Board.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1514213113/-/DCSupplemental.